New combo aims to clear hepatitis b virus in 86-Patient trial

NCT ID NCT05970289

Ongoing Disease control Sponsor: Brii Biosciences Limited Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 2 study tests whether adding the experimental drug BRII-835 to standard pegylated interferon can help people with chronic hepatitis B lose the virus surface antigen (HBsAg), a key marker of infection. Eighty-six adults on stable antiviral therapy will receive either interferon alone or with different doses of BRII-835. The goal is to see if the combination can achieve better viral control and possibly allow patients to stop long-term medication.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BRII-835 (a drug) and pegylated interferon alpha (a biologic)
What this could lead to: If successful, this combination could help more people with chronic hepatitis B clear the virus surface antigen, potentially leading to long-term disease control without daily medication.
What could go wrong: This is a mid-stage trial with only 86 participants, so results may not apply to everyone. Side effects from interferon are common, and the treatment may not work for all.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC HEPATITIS B VIRUS INFECTION

Contacts and locations

Locations

Investigative Site 61001

Kingswood, New South Wales, 2747, Australia
Investigative Site 61002

Birtinya, Queensland, 4575, Australia
Investigative Site 61003

Melbourne, Victoria, 3004, Australia
Investigative Site 65001

Singapore, 169856, Singapore
Investigative Site 65002

Singapore, 529889, Singapore
Investigative Site 66003

Bangkok, 10330, Thailand
Investigative Site 66005

Khon Kaen, 40002, Thailand
Investigative Site 66006

Nonthaburi, 11000, Thailand
Investigative Site 66008

Songkhla, 90110, Thailand
Investigative Site 82001

Busan, 49241, South Korea
Investigative Site 82002

Chuncheon, Chuncheon-si, 24253, South Korea
Investigative Site 82003

Seoul, 6351, South Korea
Investigative Site 82004

Daegu, 41566, South Korea
Investigative Site 82005

Seoul, 13496, South Korea
Investigative Site 82006

Soeul, 05505, South Korea
Investigative Site 85201

Hong Kong, HONG KONG, 999077, China
Investigative Site 85202

Hong Kong, HONG KONG, 999077, China
Investigative Site 86001

Beijing, Beijing Municipality, 100000, China
Investigative Site 86001

Beijing, Beijing Municipality, 100050, China
Investigative Site 86004

Chongqing, Chongqing Municipality, 400010, China
Investigative Site 86006

Guangzhou, Guangdong, 510630, China
Investigative Site 86007

Beijing, Beijing Municipality, 100069, China
Investigative Site 86008

Changchun, Jilin, 130021, China
Investigative Site 86011

Hangzhou, Zhengjiang, 310016, China
Investigative Site 86013

Shanghai, Shanghai Municipality, 200025, China
Investigative Site 88601

Kaohsiung, Taiwan, 80756, China
Investigative Site 88602

Taipei, Taiwan, 10041, China
Investigative Site 88603

Taipei, Taiwan, 11217, China
nvestigative Site 66007

Chiang Mai, 50200, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.